Analysis of older adults inclusion in clinical trials of FDA-approved new drugs in the United StatesDING Jing, XU Yang, YANG Yue, TIAN Li-juan449-454
Research progress on clinical efficacy evaluation of traditional Chinese medicine treatment for chronic obstructive pulmonary disease based on causal learning model frameworkWEI Wei, WANG Bo-ran, WANG Jia-yun, ZHOU Xue-zhong461-464
Research progress on the mechanism of Huisheng Oral Liquid in the auxiliary treatment of non-small cell lung cancerZHENG Mao-dong, ZHANG Ben-chang, YAN Juan465-469
Use of Data Monitoring Committees in Clinical Trials,Guidance for Industry(draft guidance)——interpret the development and practice of Data Monitoring Committee from the updated FDA guidelinesZHENG Yu, DANG Hai-xia, LIU Jun, WANG Zhong, YU Ya-nan470-475
Analysis and consideration of classification for the causality assessment of adverse events in drug clinical trialsPEI Xiao-jing, LI Hai-yan, SHEN Yi-feng, LIU Min476-480
Study and analysis of the registration characteristics of clinical trials of poly ADP ribose polymerase inhibitors based on the ClinicalTrials databaseYIN Gui-sen, DONG Bai-hui, SU Jia-hang, LIU Fen, LI Jin-lan481-487
Standardization of the first batch of national reference standard of lysozymeLIU Li-sha, HE Dong-mei, LI Jing, DONG Xin, HE Lan-ying, ZHANG Dou-sheng, REN Li-ping, FAN Hui-hong488-494
Development of the first batch of saxagliptin monohydrate national control productZHAI Chen-fei, FENG Yu-fei, LUO Chen, LIU Qian, YANG Dong-sheng495-499
Research on chemical components of Danggui Beimu Kushen Pills based on UPLC-Q-TOF-MS/MS and in-depth analysis of feature-based molecular networkSUN Yan, CHENG Mei-ling, LI Zhi-xuan, WANG Rui, WANG Ying-li, QIN Xue-mei, LIU Rui500-511